1. Assessment of Pharmacokinetic Interaction Between Gefapixant (MK‐7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin. Issue 3 (24th November 2021) Authors: McCrea, Jacqueline B.; Hussain, Azher; Ma, Bennett; Garrett, Graigory C.; Evers, Raymond; Laabs, John E.; Stoch, S. Aubrey; Iwamoto, Marian Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 3(2022) Page Start: 406 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK‐7264), a P2X3 Receptor Antagonist. Issue 1 (19th June 2021) Authors: Nussbaum, Jesse C.; Hussain, Azher; Ma, Bennett; Min, K. Chris; Evers, Raymond; Li, Yun; Garrett, Graigory; Stoch, S. Aubrey; Iwamoto, Marian Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 1(2022) Page Start: 123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Issue 1 (1st February 2022) Authors: Nussbaum, Jesse C.; Hussain, Azher; Ma, Bennett; Min, K. Chris; Chen, Qing; Tomek, Charles; Iwamoto, Marian; Stoch, S. Aubrey Journal: Pharmacology research & perspectives Issue: Volume 10:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. Issue 1 (1st January 2016) Authors: Raheem, Izzat T.; Schreier, John D.; Fuerst, Joy; Gantert, Liza; Hostetler, Eric D.; Huszar, Sarah; Joshi, Aniket; Kandebo, Monika; Kim, Somang H.; Li, Jing; Ma, Bennett; McGaughey, Georgia; Sharma, Sujata; Shipe, William D.; Uslaner, Jason; Vandeveer, George H.; Yan, Youwei; Renger, John J.; Smi... Journal: Bioorganic & medicinal chemistry letters Issue: Volume 26:Issue 1(2016) Page Start: 126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis. (15th October 2022) Authors: Ginnetti, Anthony T.; Paone, Daniel V.; Nanda, Kausik K.; Li, Jing; Busuek, Marina; Johnson, Scott A.; Lu, Jun; Soisson, Stephen M.; Robinson, Ronald; Fisher, John; Webber, Andrea; Wesolowski, Gregg; Ma, Bennett; Duong, Le; Carroll, Steven; Burgey, Christopher S.; Stachel, Shawn J. Journal: Bioorganic & medicinal chemistry letters Issue: Volume 74(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P213 - A priori prediction of CYP3A victim drug-drug interaction of MK-1 and diltiazem using physiologically-based pharmacokinetic modeling (PBPK): qualification using clinical data. (2020) Authors: Gibson, Christopher; Hartmann, Georgy; Ma, Bennett; Chain, Anne; Smith, Sean; Forman, Mark; Datta, Sandip; Bateman, Thomas; Li, Ying; Khalilieh, Sauzanne Journal: Drug metabolism and pharmacokinetics Issue: Volume 35(2020)Supplement 1 Page Start: S87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Suppression of cathepsin K biomarker in synovial fluid as a free-drug–driven process. (7th January 2019) Authors: Ma, Bennett; Wesolowski, Gregg; Luo, Bin; Lifsted, Traci; Wessner, Keith; Adamson, Gary; Glantschnig, Helmut; Lubbers, Laura S Journal: Journal of circulating biomarkers Issue: Volume 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗